5 Minutes Read
Hester Bio gets a booster shot of profit in slog overs — check dividend
KV Prasad Jun 13, 2022, 06:35 AM IST (Published)
Listen to the Article (6 Minutes)
Summary
Vaccine sales and profit sped up for the Ahmedabad-based company in the last three months of the financial year, thanks to the government drive to protect the country’s cattle from lumpy skin disease.
Shares of Ahmedabad-based Hester Biosciences surged as much as 7% in trade, taking the tally for 2024 closer to 20%, after a 12% growth in standalone annual revenue.
The pace of growth accelerated in the last three months of the financial year as the government’s immunisastion programme to prevent lumpy skin disease in cattle drove the company’s vaccine sales.
The ₹1,470-crore company, which makes vaccines for animals and poultry chicken, declared divided of ₹6 a share, the lowest in the last five years.
| Dividend date | Amount |
| May 2024 | ₹6 |
| May 2023 | ₹8 |
| June 2022 | ₹10 |
| June 2021 | ₹10 |
| May 2020 | ₹6.6 |
For the fourth quarter ended March 2024, the standalone revenue growth was 20%.
Net profit for the full year at ₹21.1 crore was still 25% less than a year ago. Over 30% of that came in the last three months.
The growth in animal healthcare division was 89% in January to March 2024, compared to the same time last year. The management expects the momentum to continue; it has projected a double-digit growth in revenue from the dairy segment.
Poultry vaccines, which make for more than half the company’s revenue grew 22% to ₹446.4 crore in the final three months of the last financial year. “We are expanding our poultry division’s product basket by introducing feed supplements, aiming to enrich our offerings and strengthen our market position,” the company said in a statement.
Company’s profitability, as measured by earnings before interest, tax, depreciation, and amortisation (EBITDA), grew 6% to ₹582.6 crore for the full year, thanks to the 37% surge in the last three months.
Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout
3 Mins Read
Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter
Daily Newsletter
